Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04073017 · ClinicalTrials.gov registry record · NA
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
A NA study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT04073017 is a NA study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 11 participants.
The verdict
NCT04073017, a NA study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is an open-label phase II basket study evaluating the ability of enterade® to reduce bowel frequency in neuroendocrine tumor (NET) patients with carcinoid syndrome and non-carcinoid syndrome.
Interventions
- DIETARY_SUPPLEMENT Enterade®
- OTHER Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2021-05-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04073017
The ClinicalTrials.gov registry entry for NCT04073017 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enterade® is the first listed.
NCT04073017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04073017 about?
NCT04073017 is a clinical study titled "Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency". This is an open-label phase II basket study evaluating the ability of enterade® to reduce bowel frequency in neuroendocrine tumor (NET) patients with carcinoid syndrome and non-carcinoid syndrome.
What is the current status of trial NCT04073017?
This trial is currently terminated. It is a NA study. The enrollment target is 11 participants. The study started on 2019-11-04. Estimated completion is 2021-05-18.
What interventions are being tested in trial NCT04073017?
The interventions under investigation include: Enterade® (DIETARY_SUPPLEMENT), Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0) (OTHER).
Who is sponsoring clinical trial NCT04073017?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.